Lilly Asia Leads USD90m Series B for Chinese Biotech Regor Therapeutics

Lilly Asia Ventures led a USD90m Series B for Regor Therapeutics, a China-based clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders, and metabolic diseases. Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China also participated in the round. Read More

Share Capital Leads USD93m Series C for China’s Binhui Biotech

Share Capital led a CNY600m (approximately USD93m) Series C for Binhui Biotech, a China-based biotechnology company focused on the development of oncology immunotherapies, with participation from CICC Capital, Vertex Ventures China, and Shenzhen Capital Group, and follow-on from Lapam Capital. Read more… Read More



(default archive template)